Title: Modulation of the RNA Interference Pathway
Patent Number: 7,709,453
Filed: May 24, 2004
Lead Inventor: Donna Ward, Isis Pharmaceuticals
The patent, its abstract states, claims "compounds, compositions, and methods … for modulating the RNAi pathway. The compositions comprise oligonucleotides targeted to nucleic acid molecules encoding EIF2C2. Methods of using these compounds for modulation of RNA interference, as well as EIF2C2 expression, and for diagnosis and treatment of disease associated with expression of EIF2C2 are provided. Also provided are compounds, compositions, and methods for modulating the expression of DDX36.
"The compositions comprise oligonucleotides targeted to nucleic acid encoding DDX36," the abstract adds. "Methods of using these compounds for modulation of DDX36 expression and for diagnosis and treatment of diseases and conditions associated with expression of DDX36 are provided."
Title: microRNAs and Uses Thereof
Patent Number: 7,709,616
Filed: May 16, 2005
Lead Inventor: Isaac Bentwich, Rosetta Genomics
The patent, its abstract states, claims "polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer."
Title: siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2
Patent Number: 7,709,629
Filed: Oct. 29, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2."
Titles: Ligand-Targeted Nanocapsules for the Delivery of RNAi and Other Agents
Application Numbers: 20100104622, 20100105139
Filed: Oct. 27, 2008
Inventor: Remco Alexander Spanjaard, Boston University School of Medicine
The invention, the patent application's abstract states, comprises "a carrier system for the delivery of therapeutic and/or diagnostic agents. … The carrier system is comprised of ligands and a biodegradable polycation for complexing polyanionic molecules such as RNAi, [with the] polycation forming a coating on the outer surface of anionic or neutral liposomes. Also disclosed is a method for using the composition to deliver to target cells and enhance cell membrane penetration of therapeutic and/or diagnostic agents."
Title: Nucleic Acid Compounds for Inhibiting Gene Expression and Uses Thereof
Application Number: 20100105134
Filed: Sept. 1, 2009
Lead Inventor: Stephen Quay, MDRNA
The patent application, its abstract states, "provides RNA molecules, for example, meroduplex ribonucleic acid molecules, and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene."
Title: H19 Silencing Nucleic Acid Agents for Treating Rheumatoid Arthritis
Application Number: 20100105759
Filed: Jan. 16, 2008 PCT Filed: Jan. 16, 2008
Inventor: Abraham Hochberg, Hebrew University of Jerusalem
"The invention relates to the treatment of rheumatoid arthritis, particularly to the use of nucleic acid agents capable of silencing H19 for the treatment of rheumatoid arthritis," the patent application's abstract states. "The invention provides methods for ameliorating rheumatoid arthritis and symptoms associated therewith, utilizing gene silencing oligonucleotides such as small interfering RNA agents directed to H19."
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
Application Number: 20100105933
Filed: Dec. 17, 2009
Lead Inventor: Tongqian Chen, Merck
The invention "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules," the patent application's abstract states. "The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … small nucleic acid molecules … to relevant cells and/or tissues, such as in a subject or organism.
"Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject, or organism," the abstract adds. "The compositions described herein are generally referred to as formulated molecular compositions or lipid nanoparticles."